Vilya

Introducing Vilya-1—an all-atom foundation model designed to accurately model and design macrocycles and peptides with non-canonical chemistry, creating new possibilities for drug discovery. Vilya-1 sets a new state-of-the-art for macrocycle structure prediction and, unlike existing methods, performs equally well on peptides built from non-canonical amino acids, opening the door to a new world of computationally-designed molecules with attractive drug-like properties. At Vilya, we believe modern peptide therapeutics require far more than binding alone. Achieving the right balance of stability, permeability, and specificity often demands chemical diversity beyond what canonical amino acids can offer. Reaching challenging intracellular targets means moving past the limits of existing design tools and into previously unexplored chemical space. 🔗 Learn more and read the technical report: https://lnkd.in/gw99UPkW 🔗 Join us: https://lnkd.in/gGRhYGzP

Our updated website is live! Connecting science, computation, and collaboration. We’re excited to share our new website and refreshed brand identity — capturing how Vilya unites computation, chemistry and experimental biology to design de novo macrocyclic therapeutics with precision. Created in close collaboration with the design studio Eatch Interactive, the platform is built for connection — speaking to scientists, pharma partners, and investors who share our ambition to expand what’s possible in drug discovery. Discover the new Vilya: https://vilyatx.com/

Vilya will be at BIO-EUROPE 2025 in Vienna, Austria from November 3–5. Our CEO & President, Cyrus Harmon, PhD, and our VP of Operations, Daniel W., will be there to connect with potential partners and explore opportunities to advance computational innovation in macrocyclic peptide discovery. If you’re attending, we’d love to meet with you! You can find us through partneringONE®. #BIOEUROPE #DrugDiscovery #Partnerships #Biotech #Vilya

Vilya Featured in Nature Biotechnology’s Editor’s Pick We’re honored that Nature Biotechnology has selected Vilya for its Editor’s Pick, recognizing our work to advance macrocycle drug discovery and design. Our mission is to unlock the potential of ‘Goldilocks’ macrocycles, molecules that can engage challenging protein–protein interfaces, previously requiring large molecules such as antibodies, while remaining small enough for oral delivery. These powerful molecules could address proteins once considered ‘undruggable’, opening the door to new treatments in immunology, oncology, and beyond. The feature highlights our innovative platform developed by co-founder and CTO Patrick Salveson, Ph.D. together with a world-class team of scientists, engineers, and the leadership of Cyrus Harmon. Together, we’re advancing a pipeline that begins with our integrin α4β7 program for inflammatory bowel disease, with more programs on the horizon. We’re proud to be pushing the boundaries of drug design and look forward to sharing more as we move our pipeline forward. 🔗 Read the full feature here: https://lnkd.in/g24zZtAA #Vilya #DrugDiscovery #Macrocycles #Biotechnology #NatureBiotechnology

We’re honored to be featured in GeekWire’s latest roundup of Seattle-area biotech innovators and thrilled that Vilya is among the spotlighted companies! As a two site company rooted in Seattle and innovating in Seattle and South San Francisco, we are grateful to both communities for their world class scientific talent, pioneering research institutions, and collaborative spirit that fuel our mission: creating a novel class of medicines to precisely target disease biology by computationally exploring uncharted chemical space. Thank you to GeekWire for featuring our work, to JPMorganChase for presenting the GeekWire 200, and to our team, partners, and investors for powering our journey to transform drug discovery. https://lnkd.in/gnksz_sP

Vilya is headed to BIO 2025! Join Cyrus Harmon, PhD (CEO & President) and Daniel W. (VP, Operations) in Boston, June 16–19 to explore how we are harnessing the power of our platform to go after previously impossible targets. Find us through the Conference Partnering System or email us at partnering@vilyatx.com #BIO2025 #Vilya #Partnering #DrugDiscovery #Macrocycles

🎗️ Heading to ASCO 2025? Let’s Connect! Vilya’s CEO & President, Cyrus Harmon, Ph.D., will be at the 2025 ASCO Annual Meeting in Chicago, IL, May 30–June 3. ASCO brings together the brightest minds in oncology to advance cancer research, patient care, and innovation. Vilya is proud to be part of this vibrant community, working at the intersection of macrocycle drug discovery and precision oncology. If you’re attending and would like to discuss collaborations, science, or our work at Vilya, send a DM or email us at info@vilyatx.com. We’d love to meet! #ASCO25 #DrugDiscovery #Biotech #Macrocycles #CancerResearch

We’re Hiring: Director, Business Development at Vilya 📍 Seattle, WA or South San Francisco, CA | Full-Time At Vilya, we’re on a mission to cure the incurable. As a computational biotechnology company, we are pioneering a new class of precision medicines that target disease biology with previously unimaginable specificity. Our platform empowers us to tackle some of the most challenging and untreatable diseases. We’re looking for a Director of Business Development to join our growing team. This is a high-impact, strategic role reporting directly to the CEO — ideal for someone passionate about innovation, partnerships, and bringing transformative science to patients. In This Role, You Will: - Identify and execute strategic partnerships that fuel growth - Lead deal negotiations and due diligence across licensing, JVs, and collaborations - Analyze market trends and scout opportunities to expand our pipeline - Collaborate with R&D, legal, finance, and executive leadership - Represent Vilya in engagements with pharma, biotech, academia, and investors What We’re Looking For: - 8+ years in biotech/pharma biz dev (startup experience strongly preferred) - Proven track record of high-value deal-making in oncology or immunology - Deep industry network and strategic vision - Exceptional leadership, communication, and analytical chops Why Vilya: - Work at the cutting edge of drug design in a bold, mission-driven company - Competitive compensation ($192K–$244K), equity, and generous benefits - Flexible time off, wellness perks, and professional development support Interested? Visit Vilya's Careers Page. Let’s build the future of medicine — together. #Vilya #BiotechJobs #BusinessDevelopment #BiotechCareers #Hiring #DrugDiscovery #LifeSciences https://lnkd.in/dDGjP-Bi